Antibody-Mediated Protection Against Symptomatic COVID-19 Can Be Achieved at Low Serum Neutralizing Titers
Investigators showed that a half-life–extended monoclonal antibody provided about 50% protection against symptomatic COVID-19 in SARS-CoV-2–naïve adults at serum neutralizing antibody titers on the order of 1:30.
[EMBO Journal] Using a variety of in vitro and in vivo techniques, researchers showed that metastatic prostate cancer cells acquire a specific Na+/Ca2+ signature required for persistent invasion.
[Molecular Cell] Investigators explored the role of minor intron-containing genes and minor spliceosome in cancer, taking prostate cancer as an exemplar.
[Nature Communications] The authors uncovered dual-phosphorylated form of sterol regulatory element-binding protein 1 (SREBF1), pY673/951-SREBF1 that acts as an androgen sensor, and dissociates from androgen receptor in androgen deficient environment, followed by nuclear translocation.